Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir

Goal. Paritrapeprir / ritonavir / ombitasvir / dasabuvir on the clinical and laboratory parameters, including the subpopulation composition of lymphocytes, in patients with compensated cirrhosis in the outcome of chronic hepatitis C.
Materials and methods. The study included patients with compensated liver cirrhosis class A (no more than 6 on the Child – Turcotte – Pugh scale), in the outcome of chronic hepatitis C, genotype 1b (group 1, n = 28). The comparison group (group 2, n = 25) consisted of patients comparable in terms of gender and main study parameters, not receiving antiviral therapy.
Results. A stable virologic response was 96,8%. There were no serious adverse events requiring treatment reversal. As a result of treatment, there was a disappearance or a significant decrease in the severity of asthenovegetative and dyspeptic syndromes, a reduction in liver size, an improvement in liver functional parameters (biochemical response), and normalization of the balance of the cellular immunity by increasing CD3 +, CD4 +, CD8 + – CD16 + lymphocyte counts.
The conclusion. Etiotropic therapy with paritrapeprir /ritonavir / ombitasvir / dasabuvir is well tolerated by patients with compensated cirrhosis in the outcome of chronic hepatitis C, has high efficacy, positively influences the dynamics of clinical manifestations, and also helps reduce the imbalance of the cellular immunity.

1. Sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2016 godu: Gosudarstvennyy doklad [On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2016: State report] – Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka [Federal Service for Supervision of Consumer Rights Protection and Human Welfare], 2017. – 220 p.

2. Chulanov V.P. Terapevticheskiy arkhiv. – 2015. – № 11. – P. 5–10.

3. Kozlov V.K. Chronic hepatitis C: immunopathogenesis, aspects of diagnosis and the modern strategy of comprehensive treatment: a guide for doctors. St. Petersburg: Alter Ego. 2009.

4. Lobzin Yu.V. Zhurn. mikrobiologii, epidemiologii i immunobiologii. – 2007. – № 6. – 75 -84.

5. Popova L.L. Features of the immune response of patients with viral hepatitis C on the background of antiviral therapy. Monograph. “Publishing House As City” Samara 2012. – 110 p.

6. Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, Orr C, Masur H, Kottilil S. Rapid changes in peripheral lymphocyte concentrations during the treatment of chronic hepatitis C infection Hepatol Commun. 2017 Sep, 1 (7): 586-594. doi: 10.1002/hep4.1074. Epub 2017 24 июля.

7. Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. Virus-induced viral cell proliferation of the hepatitis virus includes cells derived from monocytes and the OX40 / OX40L axis. J Hepatol. 2018 Mar, 68 (3): 421-430. doi: 10.1016/j.jhep.2017.10.021.Epub 2017 1 ноября.

8. Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, Carey I. Immunological predictors do not respond to the direct effect of antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Open Forum Infect Dis. 2017 3 апреля; 4 (2): ofx067. doi: 10.1093/ofid/ofx067.eCollection 2017 Spring.

9. Navarta LM, Espul CA, Acosta-Rivero N. The high prevalence of various autoantibodies in a population infected with the hepatitis C virus. APMIS. 2018, 126 (6): 515-522. doi: 10.1111/apm.12850.

10. Matsumoto K, Kikuchi K, Kajiyama Y, Takano Y, Mabuchi M, Doi S, Sato K, Miyakawa H, Yasuda I. Development of autoimmune hepatitis during antiviral therapy of direct action in chronic hepatitis C virus infection: a report on the situation. Intern Med. 2018 April 27. Doi: 10.2169/internalmedicine.0613-17.